Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance - PubMed (original) (raw)
. 2007 Jul 26;26(34):4969-78.
doi: 10.1038/sj.onc.1210300. Epub 2007 Feb 19.
Affiliations
- PMID: 17310998
- DOI: 10.1038/sj.onc.1210300
Free article
Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance
J Staub et al. Oncogene. 2007.
Free article
Abstract
To investigate the mechanism by which HSulf-1 expression is downregulated in ovarian cancer, DNA methylation and histone acetylation of HSulf-1 was analysed in ovarian cancer cell lines and primary tumors. Treatment of OV207 and SKOV3 by 5-aza-2'-deoxycytidine resulted in increased transcription of HSulf-1. Sequence analysis of bisulfite-modified genomic DNA from ovarian cell lines and primary tumors without HSulf-1 expression revealed an increase in the frequency of methylation of 12 CpG sites in exon 1A. Chromatin immunoprecipitation assays showed an increase in histone H3 methylation in cell lines without HSulf-1 expression. To assess the significance of HSulf-1 downregulation in ovarian cancer, OV167 and OV202 cells were transfected with HSulf-1 siRNA. Downregulation of HSulf-1 expression in OV167 and OV202 cells lead to an attenuation of cisplatin-induced cytotoxicity. Moreover, patients with ovarian tumors expressing higher levels of HSulf-1 showed a 90% response rate (27/30) to chemotherapy compared to a response rate of 63% (19/30) in those with weak or moderate levels (P=0.0146, chi(2) test). Collectively, these data indicate that HSulf-1 is epigenetically silenced in ovarian cancer and that epigenetic therapy targeting HSulf-1 might sensitize ovarian tumors to conventional first-line therapies.
Similar articles
- Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer.
Shridhar V, Bible KC, Staub J, Avula R, Lee YK, Kalli K, Huang H, Hartmann LC, Kaufmann SH, Smith DI. Shridhar V, et al. Cancer Res. 2001 May 15;61(10):4258-65. Cancer Res. 2001. PMID: 11358853 - Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer.
Liu P, Khurana A, Rattan R, He X, Kalloger S, Dowdy S, Gilks B, Shridhar V. Liu P, et al. Cancer Res. 2009 Jun 1;69(11):4843-50. doi: 10.1158/0008-5472.CAN-08-3065. Cancer Res. 2009. PMID: 19487294 Free PMC article. - Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
Abbosh PH, Montgomery JS, Starkey JA, Novotny M, Zuhowski EG, Egorin MJ, Moseman AP, Golas A, Brannon KM, Balch C, Huang TH, Nephew KP. Abbosh PH, et al. Cancer Res. 2006 Jun 1;66(11):5582-91. doi: 10.1158/0008-5472.CAN-05-3575. Cancer Res. 2006. PMID: 16740693 - Epigenetic Pathways Offer Targets for Ovarian Cancer Treatment.
Gyparaki MT, Papavassiliou AG. Gyparaki MT, et al. Clin Breast Cancer. 2018 Jun;18(3):189-191. doi: 10.1016/j.clbc.2017.09.009. Epub 2017 Sep 19. Clin Breast Cancer. 2018. PMID: 29042129 Review. No abstract available. - Epigenetic regulation of glycosylation and the impact on chemo-resistance in breast and ovarian cancer.
Greville G, McCann A, Rudd PM, Saldova R. Greville G, et al. Epigenetics. 2016 Dec;11(12):845-857. doi: 10.1080/15592294.2016.1241932. Epub 2016 Sep 30. Epigenetics. 2016. PMID: 27689695 Free PMC article. Review.
Cited by
- Studying nanoscale structural alterations in cancer cells to evaluate ovarian cancer drug treatment, using transmission electron microscopy imaging.
Adhikari P, Hasan M, Sridhar V, Roy D, Pradhan P. Adhikari P, et al. Phys Biol. 2020 Mar 25;17(3):036005. doi: 10.1088/1478-3975/ab6abb. Phys Biol. 2020. PMID: 31931492 Free PMC article. - A role for candidate tumor-suppressor gene TCEAL7 in the regulation of c-Myc activity, cyclin D1 levels and cellular transformation.
Chien J, Narita K, Rattan R, Giri S, Shridhar R, Staub J, Beleford D, Lai J, Roberts LR, Molina J, Kaufmann SH, Prendergast GC, Shridhar V. Chien J, et al. Oncogene. 2008 Dec 11;27(58):7223-34. doi: 10.1038/onc.2008.360. Epub 2008 Sep 22. Oncogene. 2008. PMID: 18806825 Free PMC article. - Development of novel monoclonal antibodies and immunoassays for sensitive and specific detection of SULF1 endosulfatase.
Yang YW, Phillips JJ, Jablons DM, Lemjabbar-Alaoui H. Yang YW, et al. Biochim Biophys Acta Gen Subj. 2021 Feb;1865(2):129802. doi: 10.1016/j.bbagen.2020.129802. Epub 2020 Dec 1. Biochim Biophys Acta Gen Subj. 2021. PMID: 33276062 Free PMC article. - EZH2/hSULF1 axis mediates receptor tyrosine kinase signaling to shape cartilage tumor progression.
Lin ZS, Chung CC, Liu YC, Chang CH, Liu HC, Liang YY, Huang TL, Chen TM, Lee CH, Tang CH, Hung MC, Chen YH. Lin ZS, et al. Elife. 2023 Jan 9;12:e79432. doi: 10.7554/eLife.79432. Elife. 2023. PMID: 36622753 Free PMC article. - Global analysis of DNA methylation by Methyl-Capture sequencing reveals epigenetic control of cisplatin resistance in ovarian cancer cell.
Yu W, Jin C, Lou X, Han X, Li L, He Y, Zhang H, Ma K, Zhu J, Cheng L, Lin B. Yu W, et al. PLoS One. 2011;6(12):e29450. doi: 10.1371/journal.pone.0029450. Epub 2011 Dec 22. PLoS One. 2011. PMID: 22216282 Free PMC article.